Aurinia Pharmaceuticals Inc. (AUPH)

Recent SEC filings show rising LUPKYNIS sales, positive operating cash flow, and a strong liquidity buffer (about $443M cash/investments at 2026-06-30) with limited funded-debt risk. FY2025 headline earnings were boosted by a large, non-recurring tax benefit, so earnings-based multiples look artificially low versus normalized profitability. On cash-flow and EV/EBITDA measures the valuation appears reasonable, with the main fundamental risk being heavy dependence on a single product and biotech regulatory/competitive uncertainty.

Aurinia's Q2 print (2026-08-06, announced confidence) — EPS beat ($0.29 vs $0.16), revenue +18.9%, reaffirmed 2026 guidance, and a large buyback retiring 16.82% of shares — anchors a constructively received but only partially digested setup; the numeric sentiment delta is indeterminate (sparse baseline, 1 scored item) with an item-level read of cooling from a positive May–July baseline, and the Red-Flag Screen is clean (no cap applied).

Bullish trend stack: price 16.96 above SMA20 16.37, SMA50 15.84, SMA200 15.51, EMA9 16.35, EMA21 16.20 and daily VWAP 16.68. Momentum confirming: RSI14 61.82 (strong, not overbought), MACD fresh bullish cross (line 0.15 > signal 0.13, histogram +0.02) and ADX14 25.78 rising with price above all MAs (uptrend strength, not a downtrend). 2026-09-16 broke the 3-week 15.90-16.52 consolidation on +5.1% with 1.17M shares vs ~0.9M average, closing near the day high. One weak signal: Williams %R -0.89 (short-term stretched at the top of the 14-day range), which is why the entry is a limit at the breakout retest rather than chasing the breakout. Score 4.